Sign in to view content

Avacincaptad Pegol, A Novel C5 Inhibitor, Reached Statistical Significance in a Pivotal Clinical Trial for Geographic Atrophy Secondary to Dry AMD

Baruch D. Kuppermann, MD, PhD

Video
Published 2020

Related

Safety and Efficacy of SC Elamipretide to Treat Noncentral Geographic Atrophy: ReCLAIM-1 Results and Phase II ReCLAIM-2 Baseline Characteristics
David R Lally, MD
Annual Meeting Talks
2021
Twelve Month Safety and Efficacy Outcomes from a Phase 2 Study of APL-2 in Patients with Geographic Atrophy
David S. Boyer, MD
Updates from the Field
2017
Episode 19: LEAD Trial for Use of Nanopulse Laser for Dry AMD with Dr. Robyn Guymer
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018

Category: AMD-Neovascular

See more